Controlled access to lumasiran in primary hyperoxaluria type 1: evaluation of a new access route for orphan drugs in the Netherlands
Lisa J. Deesker(Emma Kinderziekenhuis), Jaap W. Groothoff(University of Amsterdam), Carla E. M. Hollak(Centre For Development Studies), Azam Nurmohamed, Nicole C. A. J. van de Kar(Radboud University Nijmegen), Eiske M. Dorresteijn(Erasmus MC), David Severs(Erasmus MC), Casper Franssen(University Medical Center Groningen), Sander F. Garrelfs(Emma Kinderziekenhuis), Ankoor Roy(National Health Insurance Fund)
Cited by 6
Related Papers
Elevated globotriaosylsphingosine is a hallmark of Fabry disease
|Proceedings of the National Academy of Sciences|2008|725
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1
|New England Journal of Medicine|2021|505
Characterization of Classical and Nonclassical Fabry Disease: A Multicenter Study
|Journal of the American Society of Nephrology|2016|421
COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration
|Nephrology Dialysis Transplantation|2020|411
Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document
|Orphanet Journal of Rare Diseases|2015|345